A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

While some new medications have helped advance the treatment of hypertrophic cardiomyopathy, experts say improvements in ...

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...

Hypertrophic cardiomyopathy (HCM ... and the most appropriate investigations for persons suspected of having HCM. Treatment strategies for the disease and its complications are presented briefly.